TrialInvestigational new drugs2021

Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913.

Yoshiro Nakahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.